SPL026 With or Without SSRIs in Participants With MDD
- Registration Number
- NCT05553691
- Lead Sponsor
- Small Pharma Ltd
- Brief Summary
The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine \[DMT\] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- MDD diagnosis
- Previously tried at least one approved method of treatment for their depression
- No monoamine oxidase-inhibitor class antidepressants for at least 3 months
- Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, laboratory tests of blood and urine
- No psychedelic drug use in the 6 months before dosing until the end of the study
- Willing to follow the contraception requirements of the trial
- Willing to be contacted by email and video call, and have online access
- Able to give fully informed written consent
- Test Cohort only: currently on a stable dose of an unspecified single SSRI alone and not in combination with any other psychiatric medications, for at least 6 weeks prior to Screening with no intention of making any changes
- Control Cohort only: no antidepressant medication for 6 months before dosing
Exclusion Criteria
- Substance use disorder
- Current or clinically relevant history of a psychotic disorder, or first-degree relatives with a clinically relevant history of a psychotic disorder
- Significant history of mania
- Significant risk of suicide
- Clinically relevant abnormal findings at the screening assessment
- Blood pressure, heart rate, or QTcF outside the acceptable ranges
- Acute or chronic illness (other than MDD) or infection
- Clinically relevant abnormal medical history or concurrent medical condition (other than MDD)
- Use of any serotonergic psychedelics within 6 months prior to dosing
- Patients of child-bearing potential who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception
- History of a severe adverse reaction to any drug or sensitivity to serotonergic psychedelic drugs
- Use of over-the-counter or prescribed medication (excluding oral contraceptives, hormone replacement therapy and SSRIs [Test Cohort only]) within previous 28 day before dose of trial medication; or paracetamol or ibuprofen within 4 hours prior to dosing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Test Cohort SPL026 Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion. Control Cohort SPL026 Patients who are not currently taking any pharmacological treatment for their depression. Patients will be administered a single dose of SPL026 by intravenous infusion.
- Primary Outcome Measures
Name Time Method Safety & tolerability: Lab biochemistry Screening, Day -1 and Day 1 Values of potential clinical importance
Safety & tolerability: Vital signs - Heart Rate Screening to Day 2 Heart rate
Safety & tolerability: Adverse Events Screening to End-of-Study Follow-up (Day 29) Adverse events (AEs)
Safety & tolerability: Vital signs - Blood pressure Screening to Day 2 Blood pressure
Safety & tolerability: Vital signs - Temperature Screening to Day 2 Temperature
Safety & tolerability: Electrocardiogram Screening to Day 2 QTcX intervals
Safety & tolerability: Suicidal Ideation Screening to End-of-Study Follow-up (Day 29) Columbia-Suicide Severity Rating Scale
- Secondary Outcome Measures
Name Time Method Challenging Experience Questionnaire (CEQ) Day 1 (dosing day) CEQ in the Test Cohort compared to the Control Cohort
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) Day -1, Day 15 and Day 29 WEMWBS in the Test Cohort compared to the Control Cohort
Evaluation of plasma levels of DMT 2, 5, 7, 10, 11, 13, 15, 30, 60, 120, 240 minutes post-dose Pharmacokinetic parameter calculation in the Test Cohort compared to the Control Cohort
Mystical Experience Questionnaire (MEQ) Day 1 (dosing day) MEQ in the Test Cohort compared to the Control Cohort
Ruminative Responses Scale (RRS) Day -1 and Day 29 RRS in the Test Cohort compared to the Control Cohort
Trial Locations
- Locations (2)
Mac Clinical Research
🇬🇧Manchester, Greater Manchester, United Kingdom
MAC Clinical Research
🇬🇧Liverpool, Prescot, United Kingdom